• 1
    Blum KA, Lozanski G, Byrd JC. Adult Burkitt leukemia and lymphoma. Blood. 2004;104:30093020.
  • 2
    Mead GM, Barrans SL, Qian W, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008;112:22482260.
  • 3
    Mead GM, Sydes MR, Walewski J, et al. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002;13:12641274.
  • 4
    Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer. 2002;94:14921499.
  • 5
    Bernstein JI, Coleman CN, Strickler JG, Dorfman RF, Rosenberg SA. Combined modality therapy for adults with small noncleaved cell lymphoma (Burkitt's and non-Burkitt's types). J Clin Oncol. 1986;4:847858.
  • 6
    Magrath IT, Janus C, Edwards BK, et al. An effective therapy for both undifferentiated (including Burkitt's) lymphomas and lymphoblastic lymphomas in children and young adults. Blood. 1984;63:11021111.
  • 7
    Barnes JA, Lacasce AS, Feng Y, et al. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. Ann Oncol. 2011;22:18591864.
  • 8
    Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006;106:15691580.
  • 9
    Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Database: Incidence - SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases, Nov 2011 Sub (1973–2009 varying) - Linked To County Attributes - Total U.S., 1969–2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based on the November 2011 submission; 2012.
  • 10
    Surveillance Research Program, National Cancer Institute SEER*Stat software, version 8.0.2; 2013.
  • 11
    NAACCR Race and Ethnicity Work Group.NAACCR Guideline for Enhancing Hispanic/Latino Identification: Revised NAACCR Hispanic/Latino Identification Algorithm [NHIA v2.2.1]. Revised September 12, 2011. Accessed April 26, 2012.
  • 12
    Hakulinen T, Seppa K, Lambert PC. Choosing the relative survival method for cancer survival estimation. Eur J Cancer. 2011;47:22022210.
  • 13
    Nelson CP, Lambert PC, Squire IB, Jones DR. Flexible parametric models for relative survival, with application in coronary heart disease. Stat Med. 2007;26:54865498.
  • 14
    Eloranta S, Adolfsson J, Lambert PC, et al. How can we make cancer survival statistics more useful for patients and clinicians: an illustration using localized prostate cancer in Sweden. Cancer Causes Control. 2013;24:505515.
  • 15
    Cronin KA, Feuer EJ. Cumulative cause-specific mortality for cancer patients in the presence of other causes: a crude analogue of relative survival. Stat Med. 2000;19:17291740.
  • 16
    Andersson TM, Dickman PW, Eloranta S, Lambert PC. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Med Res Methodol. 2011;11:96.
  • 17
    Cronin K, Mariotto A, Scoppa S, Green D, Clegg L.Differences Between Brenner et al. and NCI Methods for Calculating Period Survival. Technical Report 2003–02. Statistical Research and Applications Branch, National Cancer Institute [serial online] 2003. Accessed February 19, 2013.
  • 18
    Brenner H, Gefeller O, Hakulinen T. Period analysis for ‘up-to-date’ cancer survival data: theory, empirical evaluation, computational realisation and applications. Eur J Cancer. 2004;40:326335.
  • 19
    Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:31213127.
  • 20
    Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-likechemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7:379391.
  • 21
    Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood. 2010;116:20402045.
  • 22
    Ribrag V, Koscielny S, Bouabdallah K, et al.Addition of Rituximab Improves Outcome of HIV Negative Patients with Burkitt Lymphoma Treated with the Lmba Protocol: Results of the Randomized Intergroup (GRAALL-Lysa) LMBA02 Protocol. (IGR sponsored LMBA02, NCT00180882). American Society of Hematology Annual Meeting Abstracts. 2012;120: Abstract 685.
  • 23
    Evens AM, Islam N, Carson KR, et al.A phase 2 clinical trial adding rituximab to CODOX-M/IVAC for untreated Burkitts lymphoma: correlative analysis of serum and CSF rituximab levels. American Society of Hematology Annual Meeting Abstracts. 2012;120: Abstract 1640.
  • 24
    Kelly JL, Toothaker SR, Ciminello L, et al. Outcomes of patients with Burkitt lymphoma older than age 40 treated with intensive chemotherapeutic regimens. Clin Lymphoma Myeloma. 2009;9:307310.
  • 25
    Cairo MS, Sposto R, Perkins SL, et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Br J Haematol. 2003;120:660670.
  • 26
    Shenoy PJ, Malik N, Nooka A, et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer. 2011;117:25302540.
  • 27
    Flowers CR, Fedewa SA, Chen AY, et al. Disparities in the early adoption of chemoimmunotherapy for diffuse large B-cell lymphoma in the United States. Cancer Epidemiol Biomarkers Prev. 2012;21:15201530.
  • 28
    Kent EE, Morris RA, Largent JA, Ziogas A, Sender LS, Anton-Culver H. Socioeconomic impacts on survival differ by race/ethnicity among adolescents and young adults with non-Hodgkin's lymphoma. J Cancer Epidemiol. 2010;2010:824691.
  • 29
    Keegan TH, Clarke CA, Chang ET, Shema SJ, Glaser SL. Disparities in survival after Hodgkin lymphoma: a population-based study. Cancer CausesControl. 2009;20:18811892.
  • 30
    Costa LJ, Xavier AC, Wahlquist AE, Hill EG. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood. 2013;121:48614866.
  • 31
    Clarke CA, Glaser SL, Dorfman RF, Bracci PM, Eberle E, Holly EA. Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications. Cancer Epidemiol Biomarkers Prev. 2004;13:138143.
  • 32
    Clarke CA, Undurraga DM, Harasty PJ, Glaser SL, Morton LM, Holly EA. Changes in cancer registry coding for lymphoma subtypes: reliability over time and relevance for surveillance and study. Cancer Epidemiol Biomarkers Prev. 2006;15:630638.
  • 33
    Wasterlid T, Jonsson B, Hagberg H, Jerkeman M. Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. Leuk Lymphoma. 2011;52:20902096.
  • 34
    Oriol A, Ribera JM, Bergua J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients. Cancer. 2008;113:117125.
  • 35
    Rodrigo JA, Hicks LK, Cheung MC, et al. HIV-Associated Burkitt Lymphoma: Good Efficacy and Tolerance of Intensive Chemotherapy Including CODOX-M/IVAC with or without Rituximab in the HAART Era. Adv Hematol. 2012;2012:735392.